Save the date for an in-person Investor Day with Valneva, discussing the Company’s current vaccine pipeline, commercial products and future directions.

The event will highlight Valneva’s core near- and mid-term value drivers: its BLA-stage chikungunya virus (CHIKV) vaccine candidate, including pre-commercial preparations and market access activities, and its Phase 3 Lyme disease vaccine candidate (Partner: Pfizer). Valneva will also provide insight into select pre-clinical development programs, followed by a financial overview.

A live Q&A session will follow the formal presentations. *The event will also be webcast live with opportunity for virtual attendees to participate in the Q&A.